- Home
- KROS
as 07-26-2024 4:00pm EST
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | LEXINGTON |
| Market Cap: | 1.8B | IPO Year: | 2020 |
| Target Price: | $88.67 | AVG Volume (30 days): | 378.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.15 | EPS Growth: | N/A |
| 52 Week Low/High: | $27.02 - $73.00 | Next Earning Date: | 08-05-2024 |
| Revenue: | $234,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 4181.46% | Revenue Growth (next year): | 23.48% |
Stock Insider Trading Activity of Keros Therapeutics Inc. (KROS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Regnante Keith | KROS | Chief Financial Officer | Nov 4 '23 | Sell | $45.29 | 40,000 | $1,811,600.00 | 0 | SEC Form 4 |
Latest Keros Therapeutics Inc. News
KROS Breaking Stock News: Dive into KROS Ticker-Specific Updates for Smart Investing
Simply Wall St.
21 days ago
Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
MT Newswires
a month ago
Oppenheimer Initiates Keros Therapeutics at Outperform With $102 Price Target
MT Newswires
a month ago
Keros Therapeutics Names Chief Executive Officer Jasbir Seehra as Board Chair
GlobeNewswire
a month ago
Keros Therapeutics Announces Leadership Updates
GlobeNewswire
a month ago
Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association
GlobeNewswire
2 months ago
Keros Therapeutics to Host a Corporate Update Conference Call and Webcast
GlobeNewswire
2 months ago
Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewswire
2 months ago
Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors
Compare KROS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KROS Keros Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.